Scientific Program

Conference Series Ltd invites all the participants across the globe to attend 8th World Congress on Pharmacology and Toxicology Melbourne, Australia.

Day 1 :

OMICS International Pharmacology Congress 2017 International Conference Keynote Speaker Janos szolcsanyi photo
Biography:

Janos szolcsanyi is a professor emeritus and a former head of the department of pharmacology of the University Of Pecs, Hungary. He is also a guest professor at
Heidelberg, Chapel Hill UNC, USA, a visiting scientist and consultant in several universities and drug firms

Abstract:

Neuropeptide somatostatin acts on G-protein-coupled receptors of two groups SRIF1 (sst2, sst3, sst5) and SRIF2 (sst1,sst4). Agonists of SRIF1 receptors are in the therapy of endocrine and gastrointestinal abnormalities. Role of SRIF2receptors is however remained out of the focus of interest. We have revealed that from one group of capsaicin-sensitive TRPV1-expressing nociceptors, somatostatin is released in response to stimulation which elicits potent systemic antinociceptive and anti-inflammatory responses by activation sst4 receptors. The stable heptapeptide analogue of somatostatin TT-232, an sst4 agonist without endocrine (SRIF1) side effects has a potent antinociceptive action both on acute and neuropathic pain models (Seltzer, diabetic mechanical allodynia). The non-peptide sst4 superagonist (J-2156) has also pronounced antinociceptive/antiinflammatory effects in various tests whose effects are absent in ssst4 gene-deleted mice. In the sst4 knockout mice hyperalgesia, chronic (CFA) and acute arthritis are more pronounced than that of the controls. Somatostatinergic systems in brain form both long-projecting neurons and short interneurons associated with mainly sst2 receptors. Sst4 receptors are dominantly expressed in the neocortex, hippocampus CA1, olfactory bulb and that of mRNA also in neurons of the amygdala and hypothalamus. Sstr4(-/-) mice showed increased anxiety in the elevated plus maze and forced swim tests while opposite results were found after injection of sst4 agonist J-2156 (100μg/kg i.p). Sst4 agonism enhanced the stress-responsiveness of neurons of several brain regions (C-Fos) and sst4 LacZ immunoreactivity was in the cortex, hippocampus and amygdala. In the T-maze test on SAMP8 mice treatment with the sst4 agonist NNC 26-9100 enhanced learning and memory and it induced decline of Aβ (x-42) levels of the brain. Intra-hippocampal injection of the sst4 agonist L-803,087 enhanced cue-based memory formation but impaired place memory formation. The morphological and behavioral results using selective sst4 agonists and Sstr4(-/-) mice provide promising perspectives for this receptor as drug target for treating neuropathic and inflammatory pain as well as anxiety, depression, memory disorders and Alzheimer disease.

Keynote Forum

Shripad D Banavali

Asian Cellular Therapy Organization, India

Keynote: Propranolol in angiosarcoma: First major advance in decades

Time : 11:40-12:20

OMICS International Pharmacology Congress 2017 International Conference Keynote Speaker Shripad D Banavali photo
Biography:

Prof. Shripad Banavali has done his MD in Internal Medicine & Adult Oncology training in India, followed by Board Certification in Pediatrics and Fellowship in Pediatric-Hematology-Oncology in USA.  Presently he heads the Department of Medical & Pediatric Oncology at the Tata Memorial Hospital, Mumbai; India. His area of research is Drug Repurposing and development of low-cost, Metronomic Protocols for the treatment of various cancers. He has more than 170 publications. He is recipient of 5 Orations and has received the International “Barton Kamen Prize” in recognition of Research on Metronomics in Childhood cancers.

Abstract:

Background: Angiosarcomasare rare malignant tumors of vascular origin that represent a therapeutic challenge. In recent times,the combination of metronomic therapies and drug repositioning has been proposed as an effective alternative for cancer patients. We tried to explore such therapies in difficult to treat, metastatic/recurrent, angiosarcoma patients.
Methods: In vitro experiments with transformed endothelial cells were used to identify synergistic interactions between betablocker
propranolol and various chemotherapeutic drugs. This led to exploration of pilot treatment protocol containing oral propranolol along with metronomic therapies. Treatment was delivered for one year followed by oral maintenance till disease progression.
Results: Our data shows that all angiosarcoma tumors express ADRB1 and /or ADRB2 adrenergic receptor genes. Propranolol
strongly synergized with micro-tubular-targeting agent vinblastine, but only showed additive or slight antagonism with drugs routinely used for the treatment of angiosarcoma viz. doxorubicin and paclitaxel. Based on this data a combination treatment was designed using oral propranolol / weekly injectable metronomic vinblastineand methotrexate, given for up-to 1 year, followed by oral maintenance with propranolol/ etoposide/ cyclophosphamide. This regimen gave us 100% response rate in the 14 patients treated with median PFS of 10.6 months and OS of 17.8 months. The toxicity was acceptable with 3 patients having grade 3 or 4 toxicity (1 Thrombocytopenia, 1 diarrhea, 1 febrile neutropenia).
Conclusion: Our data provides strong rationale for the combination of metronomic chemotherapy and propranolol in angiosarcoma which warrants additional studies. It also illustrates the potentialof metronomics to generate innovative, yet inexpensive, targeted therapies for both high-income and low/middle income countries.